-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $13

Benzinga·12/09/2025 20:07:47
Listen to the news
Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and raises the price target from $12 to $13.